Evidence map›Paper›PMID 24789790›Full record

ArticleJournal of virology2014

Ineffectual targeting of HIV-1 Nef by cytotoxic T lymphocytes in acute infection results in no functional impairment or viremia reduction.

Justin De La Cruz, Thomas Vollbrecht, Patricia Frohnen, Hwee L Ng, Eric S Daar, Otto O Yang, Martha J Lewis

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. HIV T-cell immunogen design and delivery.Current opinion in HIV and AIDS · 2022
    Review
  2. CD8Viral immunology · 2018
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Justin De La CruzDepartment of Microbiology, Immunology and Medical Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Thomas VollbrechtDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Patricia FrohnenDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Hwee L NgDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
Eric S DaarDepartment of Medicine, Division of HIV Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA.
Otto O YangDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA Department of Microbiology, Immunology and Medical Genetics, David Geffen School of Medicine at UCLA, Los Angeles, California, USA AIDS Healthcare Foundation, Los Angeles, California, USA.
Martha J LewisDepartment of Medicine, Division of Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles, California, USA UCLA AIDS Institute, David Geffen School of Medicine at UCLA, Los Angeles, California, USA malewis@mednet.ucla.edu.
University of California, Los Angeles · USAIDS Healthcare Foundation · USBlack AIDS Institute · USHarbor–UCLA Medical Center · US

Funding

HIV-1 Excape from Inhibiton by Cytotoxic T LymphocytesR01AI043203 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, OTTO O · 1998 to 2012
$4.6M
Immune Pressure on HIV-1 Nef by Cytotoxic T LymphocytesR01AI051970 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI YANG, OTTO O · 2002 to 2011
$4.1M
HIV-1 Nef's Role in Pathogenesis in vivoR01AI083083 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LEWIS, MARTHA J · 2009 to 2012
$1.5M
NIAID NIH HHS AI043203NIAID NIH HHS AI051970NIAID NIH HHS AI083083NIAID NIH HHS R01 AI043203NIAID NIH HHS R01 AI051970NIAID NIH HHS R01 AI083083PHS HHS ULITR000124
6 · The paper itself

Abstract

The human immunodeficiency virus type 1 (HIV-1) accessory protein Nef is heavily targeted by CD8(+) T lymphocytes (CTLs) during acute infection and therefore is included in many candidate vaccines. We investigated whether CTL targeting of Nef during acute infection contributes to immune control by disrupting the function of Nef. The sequence and function of Nef in parallel with CTL responses were assessed longitudinally from peak viremia until the viremia set point in a cohort of six subjects with acute infection. All but one individual had a single founder strain. Nef-specific CTL responses were detected in all subjects and declined in magnitude over time. These responses were associated with mutations, but none of the mutations were detected in important functional motifs. Nef-mediated downregulation of CD4 and major histocompatibility complex (MHC) class I molecules was better preserved in acute infection than in chronic infection. Finally, Nef-specific CTL responses were not associated with a reduction in viremia from its acute-phase peak. Our results indicate that CTLs targeting Nef epitopes outside critical functional domains have little effect on the pathogenic functions of Nef, rendering these responses ineffective in acute infection. Importance: These data indicate that using the whole Nef protein as a vaccine immunogen likely allows immunodominance that leads to targeting of CTL responses that are rapidly escaped with little effect on Nef-mediated pathogenic functions. Pursuing vaccination approaches that can more precisely direct responses to vulnerable areas would maximize efficacy. Until vaccine-induced targeting can be optimized, other approaches, such as the use of Nef function inhibitors or the pursuit of immunotherapies such as T cell receptor gene therapy or adoptive transfer, may be more likely to result in successful control of viremia.

Indexed as

HIV-1HIV InfectionsHumansnef Gene Products, Human Immunodeficiency VirusT-Lymphocytes, CytotoxicViremianef Gene Products, Human Immunodeficiency Virusnef protein, Human immunodeficiency virus 1

Identifiers

PMID24789790
PMCPMC4097801
OpenAlexW2123088081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.